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Effect of Proton Pump Inhibitor on
Esophageal Eosinophilia
Shauna Schroeder, yKelley E. Capocelli, Joanne C. Masterson, Rachel Harris,
zCheryl Protheroe, zJames J. Lee, and Glenn T. Furuta
ABSTRACT
Objective: Differentiation between the common etiologies of dense
esophageal eosinophilia such as gastroesophageal reflux disease (GERD)
and eosinophilic esophagitis can be difficult. We hypothesized that histo-
logic features may provide diagnostic clues concerning the etiology of
esophageal eosinophilia.
Methods: We performed a retrospective chart review of 204 children with
the diagnosis of esophagitis characterized by15 eosinophils (eos) per high-
power field (HPF) in at least 1 biopsy. We then restricted our analysis to
subjects who had received at least 8 weeks of only proton pump inhibitors
(PPIs) followed by endoscopy and who had a clinicopathologic response to
this treatment. Symptoms, endoscopic findings, and pathologic descriptions
were reviewed and an eosinophil peroxidase (EPX) index was determined to
assess for degranulation/eosinophil activation.
Results: Of the 204 identified charts, 7 subjects identified met the inclusion
criteria. Five of these 7 patients showed a clinicopathologic response to
PPIs after their follow-up endoscopy, (mean peak eosinophil count: 92 vs
5 eos/HPF, and EPX index: 39.2 vs 14.6, pre- and posttreatment,
respectively). Two patients experienced initial resolution of symptoms and
esophageal eosinophilia with PPI therapy; however, within 17–23 months
they redeveloped symptoms and esophageal eosinophilia while receiving PPI
therapy at the time of a third endoscopy (mean peak eosinophil count: 40 vs
11 vs 36eos/HPF, and EPX index: 44 vs 21 vs 36.5, pre-, post- and
posttreatment, respectively). No clinicopathologic features or degranulation
patterns differentiated subjects with GERD/PPI responsive esophageal
eosinophilia from those who had transient response to PPI treatment.
Conclusions: No clinicopathologic features differentiated subjects who
responded to PPI treatment. PPI treatment can be helpful to exclude
GERD and PPI responsive esophageal eosinophilia but long-term follow-
up is critical in the management of esophagitis.
Key Words: eosinophil, eosinophil peroxidase, gastroesophageal reflux
disease, histopathology
(JPGN 2013;56: 166–172)
E sophageal eosinophilia is a histologic finding associated withgastroesophageal reflux disease (GERD) and eosinophilic
esophagitis (EoE). Initial studies of children with GERD identified
a distal eosinophilic infiltration of the squamous epithelium but the
exact numbers and distribution defining GERD are not certain (1).
Over the past decade, the diagnosis of EoE developed a new focus
on how esophageal eosinophilia is defined and even more impor-
tantly, what mechanisms underlie the inflammatory process.
This new-found interest specifically concerns the role of
proton pump inhibitor (PPI) treatments in determining etiologies. In
this regard, PPI treatment has created a certain degree of clinical
confusion and scientific controversy. PPIs can be costly and doses
necessary to effectively treat eosinophilia are not certain. Increasing
clinical experiences have also identified a subgroup of patients
with esophageal eosinophilia who experience symptoms related to
esophageal dysfunction and exhibit clinicopathologic responses to
PPI treatment; when performed, pH impedance studies are normal.
Whether this inflammation is related to GERD that has escaped
technical detection or alternative mechanisms is not certain; how-
ever, a clinical descriptor, PPI responsive esophageal eosinophilia
(PPIREE), has arisen to describe this patient population. To add
further intrigue, a recent report described 4 patients who experi-
enced an initial response to PPI treatment but subsequent clinico-
pathologic recurrence while receiving PPI treatment (2).
Thus, differentiation of inflammation associated with GERD,
EoE, and PPIREE is not a straightforward task and no definitive
clinical pathway to differentiate etiologies of esophageal eosinophilia
has been identified. Because EoE is a chronic disease that is treated
with lifelong use of diet restriction or topical corticosteroids, we have
aggressively sought to differentiate between these conditions with a
diagnostic trial of PPIs and/or use of pH monitoring probes.
To determine whether any feature may help to predict which
patients will clinically and histologically respond to PPI treatment,
we performed a retrospective analysis of children with esophagitis
who had undergone pre- and post-PPI treatment endoscopies. We
hypothesized those pediatric patients who demonstrated a clinico-
pathologic response to PPI treatment (ie, diagnosis of GERD or PPI
responsive eosinophilia) would have distinct pathologic features.
METHODS
Subject Selection
A retrospective chart review was performed of patients who
were evaluated in the Digestive Health Institute, Section of Pediatric
Gastroenterology, Hepatology, and Nutrition at Children’s Hospital
Colorado from 2000 to 2011who had received a diagnosis of
esophagitis and had undergone at least 2 esophagogastroduodeno-
scopy (EGD) procedures to assess the mucosa before and after PPI
treatment (1–2mg  kg1  day1) for at least 8 weeks. Esophagitis
was defined as>15 eosinophils (eos) per high-power field (HPF) in
at least 1 biopsy (distal, middle, or proximal) specimen as described
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previously (3,4). Subjects were excluded from this analysis if they
had incomplete treatment records, dietary modifications, and/or
initiation of topical steroid therapy (budesonide, fluticasone, cicle-
sonide) between first and second endoscopy or had gastrostomy
tubes placed for elemental diet as a treatment (5–7). Medical
records were reviewed and clinical features recorded to include
presenting symptoms, history of allergic diseases, and endoscopic
findings such as linear ridging, edema, ulcerations, microabscesses,
furrows, and esophageal stricture.
Patients were classified as PPI responders if after PPI treat-
ment their second mucosal biopsy showed 15 eos/HPF, and PPI
nonresponders if they continued to have inflammation with
>15 eos/HPF. PPI responders received a diagnosis of GERD or
PPIREE. Non-PPI responders received a diagnosis of EoE.
Histologic Assessment and Staining
All of the esophageal tissue sections were assessed indepen-
dently by a pathologist (K.C.) and 2 other research investigators
(S.S., J.M.). Reactive changes (rete peg elongation, basal cell hyper-
plasia), eosinophil number (mean of 15HPF and peak number
counted in single most densely inflamed HPF at 40 magnifi-
cation-field size 0.26 mm2, data presented as mean range), eosi-
nophil degranulation, superficial layering of eosinophils, and
presence of microabscesses were measured as previously described
(8–11). Tissueswere assessed for intercellular edema, lamina propria
fibrosis, and presence of additional immune cells. Immunostaining
was completed with an eosinophil peroxidase (EPX) antibody as
previously described. (12) Briefly, each section underwent staining
with a monoclonal antibody for EPX (hybridoma MM25–82.2.1;
Mayo Clinic Arizona, Scottsdale). Slides were assessed for eosino-
phil patchiness, degranulation, and intact eosinophils to determine an
EPX index. The present study was approved by the institutional
review board at the University of Colorado (COMIRB 07–0888).
RESULTS
Subject Identification
In the present study, we sought to determine the effect of PPI
treatment alone on patients with dense esophageal eosinophilia and
determine whether any histologic features helped discriminate
between these clinical responses. Screening of pathology and
medical records identified 204 subjects with a diagnosis of eso-
phagitis who had at least 2 EGDs performed. Primary indications
for EGDs included regurgitation, feeding difficulties, dysphagia,
vomiting, heartburn, failure to thrive, abdominal pain, and foreign
body impaction. The majority of subjects (169) were excluded
because they received a diagnosis of EoE and undergone a variety of
treatments in addition to PPI treatment before their second endo-
scopy (Fig. 1).
Of the remaining 35 patients, who had undergone at least
2 EGDs and received only PPI treatment, 27 (77%) did not have
resolution of symptoms or esophageal eosinophilia (PPI non-
responders), and thus received a diagnosis of EoE. Resolution
of esophageal eosinophilia was determined by <15 eos/HPF in
their follow-up biopsies. The final 8 patients (23%) showed
resolution of symptoms and esophageal inflammation after PPI
treatment (PPI responders). One of these patients was excluded
because of unavailable biopsies for EPX analysis. These PPI-
responsive patients received a diagnosis of either GERD or
PPIREE because no pH studies were performed to differentiate
them. Five of these patients continued with PPI treatment and
remained asymptomatic after an average of 8 months of follow-up.
Two of the remaining patients continued receiving PPI treatment
and underwent a third endoscopy because of recurrence of symp-
toms 17 and 23 months after their second endoscopy. Both of these
patients demonstrated dense eosinophilia with mean peak eosino-
phil counts of 52 and 21 eos/HPF and EPX indices of 40 and 33 at
the time of their first and third EGD, respectively. These subjects
were treated with dietary elimination and topical corticosteroids
and experienced clinical remission. Consistent with a previous
report, these 2 subjects had a transient response to PPI and were
ultimately given a diagnosis of EoE (2). Through the rest of the
present study, we will refer to PPI responders as having either
GERD or PPIREE and these transient PPI responders as having
EoE. The 27 patients who were PPI nonresponders were clinically
defined as having EoE and their histologic findings before and
after PPI are presented in Table 1. These patients had a mean peak
eosinophil count 43 22 eos/HPF at the time of their first biopsy
and after PPI therapy had a mean peak eosinophil count
62 36 eos/HPF.
Pediatric patients with diagnosis of esophageal eosinophilia (204)
Two sequential EGDs with at least one biopsy with ≥ 15 eos/hpf
PPI therapy for at least 2 months prior to second EGD
Subjects included (35)Subjects excluded (169)
Complicated/insufficient treatment history (49)
Dietary changes prior to second EGD (24)
Topical steroid treatment prior to second EGD (78)
Dietary and topical steroid prior to second EGD (8)
Elemental formula treatment prior to second EGD (10)
EoE subjects (27)
PPI nonresponders EoE
PPI responsive
subjects (7)
No biopsy available (1)
FIGURE 1. Flow diagram of included and excluded subjects.
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Clinical Features of Subjects With GERD/PPIREE
and EoE
When comparing GERD/PPIREE (5) with EoE (2), no
clinical differences were identified in ethnicity, presenting symp-
tom, history of atopic diseases, or initial endoscopic findings
(Table 2). Symptoms of dysphagia, coughing, or abdominal pain
were not specific to either patients with GERD/PPIREE or EoE. No
specific endoscopic findings differentiated GERD/PPIREE from
EoE (Table 2).
Histologic Features of the Untreated
Esophageal Mucosa of Subjects With GERD/
PPIREE and EoE
GERD/PPIREE had a higher pretreatment peak eosinophil
counts compared with EoE peak eosinophil counts, which are
shown in Table 3. Additional features of epithelial inflammation,
including eosinophil degranulation, eosinophil microabscesses,
superficial layering of eosinophils, intercellular epithelial edema,
lamina propria fibrosis, presence of other immune cells, and
reactive changes including basal cell hyperplasia and rete peg
elongation were present in both GERD/PPIREE and EoE tissues
and did not display any significant differences. Total EPX
indices as well as examination of subcategories within the
EPX index scoring paradigm (patchiness, degranulation, eosino-
phil number) were not different between GERD/PPIREE and
EoE (Table 3).
Features of Transient PPI Responders
Evaluation of the 2 subjects who had recurrence of symptoms
and esophageal eosinophilia while continuing PPI treatment did not
reveal any distinguishing clinicopathologic features. At the time of
their third endoscopy, no differences were seen in comparison to
their initial presenting symptoms (abdominal pain, vomiting, and
coughing), degree of eosinophilia (35 vs 52 and 45 vs 21 for first
and third endoscopy, respectively for each subject), or EPX index
(48 vs 40 and 40 vs 33 for first and third endoscopy, respectively for
each subject).
DISCUSSION
Because of complexities surrounding use of PPI treatment
to determine the etiology of esophageal eosinophilia, we per-
formed a retrospective study covering a time span of 11 years that
documented the mucosal response to PPI treatment in well-
defined children with dense esophageal eosinophilia. The goal
of our study was to determine whether any of these features could
help to guide clinical practice in distinguishing between these
emerging patient populations. Our search yielded a small number
of subjects who did not identify key clinical or histologic features
that suggested nonresponsiveness or responsiveness to PPIs but
3 key clinical observations were made. First, 77% (27/35) of
patients with dense esophageal eosinophilia showed no clinico-
pathologic response to PPI supporting the lack of effect of PPIs on
esophageal inflammation in EoE (3). Second, PPI treatment
reduced dense esophageal eosinophilia in 23% (8/35) of patients
treated, thus supporting the concept that dense eosinophilic
inflammation may be PP responsive (13) and that the use of
PPI is helpful as a diagnostic test for EoE. Third, a transient PPI
response was found in 6% (2/35) of children with dense esopha-
geal eosinophilia, thus emphasizing the importance of close
follow-up of patients with esophagitis (2). Taken together, these
findings support the utility of PPIs in the evaluation of dense
esophageal eosinophilia but also indicate that patients with eso-
phagitis should have long-term follow-up.
PPIs have been helpful to differentiate mucosal inflam-
mation associated with EoE from other causes. In 2 retrospec-
tive series of subjects with dense esophageal eosinophilia
(15 eos/HPF), >40% of subjects responded histologically to
PPI and no demographic, presenting symptoms, pH study, endo-
scopic, or histologic findings differentiated PPI responders from
nonresponders (14,15). In a prospective series of 35 adults with
dysphagia and dense esophageal eosinophilia (35–165 eos/HPF),
50% had symptomatic and histologic remission with adminis-
tration of PPI (16). Our results support these findings that further
describe a population of patients presenting with dense esopha-
geal eosinophilia who experience a successful response to PPI
monotherapy. Our study identified that 23% of these pediatric
patients have either GERD or PPIREE and support the utility of
PPI as a part of the diagnostic paradigm for EoE (3,4). In addition,
our study is consistent with previous works that have not
TABLE 1. PPI nonresponders—EoE histologic assessment
Patient
Peak eosinophil
count pre/post Degranulation
Reactive
changes Microabscess Patient
Peak eosinophil
count pre/post Degranulation
Reactive
changes Microabscess
1 50/severe Y/Y Y/Y Y/N 15 Moderate/40 N/N Y/Y N/N
2 15/60 N/Y N/Y N/Y 16 15/55 —/Y —/Y —/N
3 Moderate/moderate Y/Y Y/Y N/N 17 50/15 Y/N Y/Y Y/N
4 40/40 Y/Y Y/Y N/N 18 20/60 N/Y Y/Y N/Y
5 30/57 Y/Y Y/Y N/N 19 60/23 Y/Y Y/Y Y/Y
6 Mild/150 N/Y Y/Y N/Y 20 58/48 Y/Y Y/Y Y/N
7 49/57 Y/Y Y/Y Y/N 21 44/100 Y/Y Y/Y N/N
8 Mild/15 N/N N/N N/N 22 100/100 —/— —/— —/—
9 80/35 Y/Y N/Y Y/Y 23 50/100 —/Y —/Y —/N
10 28/50 N/N Y/Y Y/Y 24 72/150 Y/Y Y/Y Y/Y
11 20/40 —/Y —/Y —/Y 25 Mild/30 —/Y —/Y ——/N
12 40/80 —/Y —/Y —/Y 26 Moderate/95 —/Y —/Y —/Y
13 25/55 Y/Y Y/Y N/Y 27 35/37 —/Y —/Y —/N
14 20/50 Y/Y Y/Y Y/Y
Reactive changes—basal epithelial hyperplasia, rete peg elongation. —¼ information not available; EoE¼ eosinophilic esophagitis; PPI¼ proton pump
inhibitor.
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identified clinical or histologic pathognomonic findings that
distinguish EoE, GERD, and PPIREE (17–23).
The third finding imports the need for close clinical follow-
up of patients with recurrent or new symptoms of reflux or
dysphagia. Overlap symptoms in GERD and EoE often make it
difficult to make a clear diagnosis at the time of presentation and
the natural history of EoE continues to be investigated. Our results
further characterize an emerging group of patients with transient
response to PPI treatment. Dohil et al (2) described 4 children who
had an initial endoscopy revealing esophageal eosinophilia, a
second endoscopy after 2 months of PPI that documented histo-
logic remission, and a third endoscopy showing recurrence of
eosinophilia. Patients were asymptomatic at the time of the second
endoscopy and had recurrence of symptoms at the time of the third.
Our patients described here experienced the same transient
response. Potential explanations for this clinical course include
lack of compliance with PPI treatment, missed detection of muco-
sal inflammation at the time of the second endoscopy, variation in
allergenic exposures at the time of the second endoscopy,
decreased responses with tapered or low-dose PPI, and diminished
effect of PPIs over time. Another possible explanation is that these
transient PPI responders may initially present with GERD and later
develop EoE. The interaction between GERD and EoE is complex
and esophageal eosinophilia fromGERDmay cause changes in the
esophageal epithelium that predispose to the development of EoE
at a later time (24). The diagnosis of EoE rests on the identification
of appropriate clinicopathologic features and the elimination of
other causes of esophageal eosinophilia. The best way to exclude
GERD as an etiology for this inflammation remains uncertain. pH
monitoring of the distal esophagus can be uncomfortable, costly,
and may not capture clinically relevant reflux in a 24-hour period.
Use of PPIs can be a diagnostic test but can be costly and
compliance may be an issue. In addition, the optimal dose to treat
esophageal eosinophilia, especially dense eosinophilic inflam-
mation, is a source of fervent discussion. The emergence of
PPIREE has identified another potential mechanism for PPIs
anti-inflammatory effect, making one wonder whether PPIs also
can target cytokine production. Kedika et al (25) reported that PPIs
inhibited interleukin-6, interleukin-8, and tumor necrosis factor-a
production from esophageal epithelial cells in vitro. Cheng et al
(26) demonstrated the effect of omeprazole on eotaxin-3 pro-
duction from esophageal epithelia in vitro also. Thus, these
descriptions of transient clinicopathologic response to PPIs who
eventually were found to have EoE add to the complexity of the use
of PPIs.
To begin to address these issues, we wondered whether any
clinicopathologic features could help to differentiate GERD/
PPIREE from EoE before any PPI treatment was provided. We
wondered whether eosinophil degranulation may provide a dis-
tinguishing pattern as suggested by past works (12). Degranulation
is an indicator of eosinophil activation and others and our work
suggests that it may only be present in EoE and not GERD (27). For
instance, Mueller at al (28) found the correlation of eosinophil
numbers with degree of eosinophil degranulation was a useful
measure. Degranulation and eosinophil number were significantly
higher in patients with EoE compared with GERD. Others have
studied additional eosinophil granule proteins (eosinophil-derived
neurotoxin [EDN], EPX) to histologically differentiate patients
with EoE from those with GERD (28–30). In 1 study a significant
increase in the EDN immunostaining was found in patients with
EoE when compared with normal patients biopsies; however, there
was no correlation in the degree of extracellular EDN to infiltrating
eosinophil numbers (26). Our study did not find differences in EPX
indices for patchiness or degranulation between our patients with
GERD/PPIREE and EoE (pretreatment); however, our patients withTA
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GERD/PPIREE had significantly denser esophageal eosinophilia
compared with the above studies.
We address this specific question by identifying and analyz-
ing a narrow subset of patients who had undergone successful PPI
pre- and post-PPI treatment endoscopies without any other inter-
ventions and using a scoring system for eosinophilia that incor-
porated not only eosinophil number but also degranulation. Using
EPX indices to measure degranulation, we were not able to identify
a signature pattern that may indicate PPI responsiveness or not. EPX
staining can therefore be a clinically useful test in differentiating
etiologies of esophageal eosinophilia in patients with eosinophil
counts <15 eos/HPF but may not be as valuable when eosinophil
numbers are more dense.
Documentation of eosinophil degranulation remains an
important tool to assess tissues affected by eosinophilic inflam-
mation. Granule proteins can be measured in mucosal secretions
as well as tissue sections. Within the gastrointestinal tract,
measurements of eosinophil granule proteins in tissues and
intestinal secretions from patients with eosinophilic gastroenter-
itis, inflammatory bowel diseases, and EoE have provided docu-
mentation of eosinophil activation. Recent works have also
identified the fact that eosinophil degranulation may be a diag-
nostic feature of EoE; our previous work developed a scoring
system that incorporated the number and distribution of eosino-
phils as well as the extent of degranulation to determine
diagnostic thresholds for GERD and EoE. More important,
the criterion standard for this test to determine a diagnostic
threshold for GERD was based on GERD tissues that contained
<15 eos/HPF. With increasing experience, it is clear that some
patients with GERD, including at least 1 in our study, can have
dense eosinophilia with numbers >15 and in some circumstances
>100 eos/HPF (13). In our present study, all 5 PPI responder
subjects had either >15 eos/HPF or an EPX index of >35, the
‘‘diagnostic’’ cutoff point for EoE. Whether these patients
represent GERD with an exuberant mucosal response or PPIREE
is not certain. Molecular analysis in the future may improve our
understanding of this group.
Although our study is limited because of its retrospective
nature and small sample size, we were able to cull these unique
patient groups with a high degree of definition and certainty.
Compliance to PPI treatment, doses prescribed, and concomitant
use of unidentified treatments represent confounding variables that
could have altered results. Another possible confounder is that
allergenic exposures, whether seasonal, environmental, food, or
others, could lead to a response, but based on close follow-up of
these patients, that is unlikely. We did not perform EPX analysis on
the 27 PPI nonresponder subjects, who were found to have EoE.
Previous work has identified key histological patterns of degranu-
lation in EoE and the further expense and time required would not
add to our understanding. The small number of patients identified
with transient response to PPI likely represents that rarity of
phenomenon or subphenotype of EoE, but provides an important
clue for clinicians.
Here we performed an 11-year retrospective study of muco-
sal response to PPI treatment. Although numbers of subjects are
small, no specific clinical or endoscopic features distinguished
GERD/PPIREE from EoE. Our results support use of PPIs as a
diagnostic tool for EoE and therapeutic agent for dense esophageal
eosinophilia. Also, the identification of the potential transient
response to PPIs identifies the importance of long-term follow-up
of patients.
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